These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 12820363

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pyruvate kinase type M2: a crossroad in the tumor metabolome.
    Mazurek S, Grimm H, Boschek CB, Vaupel P, Eigenbrodt E.
    Br J Nutr; 2002 Jan; 87 Suppl 1():S23-9. PubMed ID: 11895152
    [Abstract] [Full Text] [Related]

  • 3. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells.
    Mazurek S.
    Int J Biochem Cell Biol; 2011 Jul; 43(7):969-80. PubMed ID: 20156581
    [Abstract] [Full Text] [Related]

  • 4. Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7.
    Mazurek S, Zwerschke W, Jansen-Dürr P, Eigenbrodt E.
    Oncogene; 2001 Oct 18; 20(47):6891-8. PubMed ID: 11687968
    [Abstract] [Full Text] [Related]

  • 5. Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply.
    Spoden GA, Rostek U, Lechner S, Mitterberger M, Mazurek S, Zwerschke W.
    Exp Cell Res; 2009 Oct 01; 315(16):2765-74. PubMed ID: 19563799
    [Abstract] [Full Text] [Related]

  • 6. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells.
    Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H, Friis R.
    Crit Rev Oncog; 1992 Oct 01; 3(1-2):91-115. PubMed ID: 1532331
    [Abstract] [Full Text] [Related]

  • 7. Regulation of pyruvate kinase type M2 by A-Raf: a possible glycolytic stop or go mechanism.
    Mazurek S, Drexler HC, Troppmair J, Eigenbrodt E, Rapp UR.
    Anticancer Res; 2007 Oct 01; 27(6B):3963-71. PubMed ID: 18225557
    [Abstract] [Full Text] [Related]

  • 8. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
    Wechsel HW, Petri E, Bichler KH, Feil G.
    Anticancer Res; 1999 Oct 01; 19(4A):2583-90. PubMed ID: 10470199
    [Abstract] [Full Text] [Related]

  • 9. Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complex.
    Mazurek S, Zwerschke W, Jansen-Dürr P, Eigenbrodt E.
    Biochem J; 2001 May 15; 356(Pt 1):247-56. PubMed ID: 11336658
    [Abstract] [Full Text] [Related]

  • 10. Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours.
    Mazurek S.
    Ernst Schering Found Symp Proc; 2007 May 15; (4):99-124. PubMed ID: 18811055
    [Abstract] [Full Text] [Related]

  • 11. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas.
    Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G.
    Anticancer Res; 1997 May 15; 17(4B):3153-6. PubMed ID: 9329624
    [Abstract] [Full Text] [Related]

  • 12. Pyruvate kinase type M2 and its role in tumor growth and spreading.
    Mazurek S, Boschek CB, Hugo F, Eigenbrodt E.
    Semin Cancer Biol; 2005 Aug 15; 15(4):300-8. PubMed ID: 15908230
    [Abstract] [Full Text] [Related]

  • 13. Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK).
    Oremek GM, Gerstmeier F, Sauer-Eppel H, Sapoutzis N, Wechsel HW.
    Anticancer Res; 2003 Aug 15; 23(2A):1127-30. PubMed ID: 12820359
    [Abstract] [Full Text] [Related]

  • 14. Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells.
    Mazurek S, Grimm H, Oehmke M, Weisse G, Teigelkamp S, Eigenbrodt E.
    Anticancer Res; 2000 Aug 15; 20(6D):5151-4. PubMed ID: 11326687
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Quantitative detection of tumor M2-PK in serum and plasma.
    Hugo F, Fischer G, Eigenbrodt E.
    Anticancer Res; 1999 Aug 15; 19(4A):2753-7. PubMed ID: 10470235
    [Abstract] [Full Text] [Related]

  • 17. Tumor-specific pyruvate kinase isoenzyme M2 involved in biochemical strategy of energy generation in neoplastic cells.
    Gumińska M, Ignacak J, Kedryna T, Stachurska MB.
    Acta Biochim Pol; 1997 Aug 15; 44(4):711-24. PubMed ID: 9584851
    [Abstract] [Full Text] [Related]

  • 18. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer.
    Ervens J, Fuchs H, Niemann VT, Hoffmeister B.
    J Craniomaxillofac Surg; 2008 Mar 15; 36(2):89-94. PubMed ID: 18243718
    [Abstract] [Full Text] [Related]

  • 19. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
    Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel KH.
    Anticancer Res; 1999 Mar 15; 19(4A):2599-601. PubMed ID: 10470201
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma.
    Kaura B, Bagga R, Patel FD.
    J Obstet Gynaecol Res; 2004 Jun 15; 30(3):193-6. PubMed ID: 15210041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.